They might have leaner customer support teams, simpler platforms, or more efficient pharmacy partnerships
2006;8(5 Pt 1):503-507
The following sections categorize and elucidate the ICD-10 codes most relevant to weight management
How Should Pharmacies and Telehealth Companies Respond

FDA's 2026 GLP-1 Warnings: 990 Reports and What They Mean for JoinSkinny Patients FDA has published ongoing warnings about compounded GLP-1 products generally: Dosing errors from measuring doses out of multi-dose vials Use of salt forms (like semaglutide sodium) that haven't been proven safe or effective Adverse events, including hospitalization in some cases As of May 31, 2026: 990 adverse-event reports tied to compounded semaglutide, and more than 730 tied to compounded tirzepatide - FDA notes these reports may be incomplete and don't, by themselves, establish that a compounded drug caused the reported event On April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list - a move that would close the main legal pathway for large-scale outsourcing-facility compounding of these drugs absent a shortage, with a public comment period that ran through June 29, 2026 These are industry-wide regulatory developments, not findings against JoinSkinny or any specific pharmacy named in this article

Effects on the Heart In 2009, a study with liraglutide showed improved cardiac output and protection against ischemic injury in a mouse model with 28 days follow-up (222)